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Abstract
AIM: To analyze the epidermal growth factor recep-
tor pathway substrate 8 (EPS8) expression status and 
role in colorectal carcinogenesis given that EPS8 has 
a conserved actin barbed-end capping function that is 
required for proper maturation in intestinal cells. 
METHODS: We studied 8 colon cancer cell lines and 58 
colorectal tumors (19 adenomas and 39 carcinomas). 
We performed expression microarray analysis of colon 
cancer cell lines followed by loss of heterozygosity (LOH) 
analysis and immunohistochemistry for EPS8 expression 
in colon tumors. Subsequently, we performed mutation 
analysis by direct sequencing and methylation analysis 
by bisulfite sequencing and methylation-specific poly-
merase chain reaction assays.
RESULTS: Expression microarray analysis of colon can-
cer cell lines showed overexpression of EPS8 transcript 
in all lines but RKO. Genome wide loss of heterozygos-
ity (LOH) analysis of colon tumors, showed consider-
able LOH at the EPS8 gene locus. Immunohistochemi-
cally, EPS8 was constitutively expressed in normal 
colonic mucosa with a dot-like supranuclear localization 
with accentuation at the luminal surface supporting its 
proposed role in epithelial maturation. Nineteen colon 
tumors (4 adenoma, 15 carcinoma) out of 51 (37%) 
showed strikingly tumor specific EPS8 protein loss. Of 
the remaining tumors, 5/51 (2 adenoma, and 3 car-
cinoma, 10%) showed marked overexpression, while 
27/51 tumors (53%) showed retained expression. Mu-
tation analysis revealed a missense mutation (c.794C>T, 
p.R265C) in exon 8 in RKO. The EPS8  promoter was 
also methylated in RKO, but there was no significant 
methylation in other cell lines or carcinoma specimens. 
CONCLUSION: The loss of EPS8 expression in colorec-
tal adenomas and carcinomas suggests that down 
regulation of this gene contributes to the development 
of a subset of colorectal cancers, a finding which could 
have applications in diagnosis and treatment.
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INTRODUCTION
Epidermal growth factor receptor pathway substrate 8 
(EPS8) is a 97-kDa protein that is tyrosine phosphory-
lated following stimulation of  receptor tyrosine kinases 
(RTK)[1]. EPS8 plays a role in signal transduction from 
RTK and PI3K[2,3] leading to Rac-mediated actin remod-
eling, ruffle formation and cell motility[4]. In Caenorhabditis 
elegans (C. elegans), eps-8 knockdown animals were zygotic 
lethal due to major defects in the gut, and the isoform 
EPS-8A was shown to be required for proper apical mor-
phogenesis in the intestinal cells. This phenotype was cor-
related with an actin barbed-end capping activity, which 
is present in the C terminus of  the EPS-8A isoform and 
is required for coordinately terminated elongation of  the 
microvillar actin bundle core[5]. This function of  EPS8 
protein is conserved throughout evolution[6].
EPS8 was recently shown to be overexpressed in ad-
vanced stage human cancers including colon cancer cell 
lines and specimens[7]. Our expression microarray analysis 
of  colon cancer cell lines confirmed this overexpression. 
Interestingly, there was a strikingly low level of  EPS8 
in RKO, a colon cancer cell line with a marked lack of  
constitutive β-catenin regulated transcription[8], which 
prompted us to conduct a comprehensive immunohisto-
chemical, genetic, and epigenetic analysis of  EPS8 altera-
tions in colorectal cell lines and patient specimens.
MATERIALS AND METHODS
Patients and samples
We studied 8 colon cancer cell lines (RKO, HCA7, KM12, 
LoVo, DLD1, HCT116, SW48, LIM1215) and 58 colorec-
tal tumors (19 adenomas and 39 carcinomas) of  which 
21 tumors (4 adenomas and 17 carcinomas) belong to a 
well characterized series of  familial colon cancer type X 
(FCC-X). 15 adenomas and 22 carcinomas were sporadic. 
Clinicopathological characteristics of  these cohorts are 
available in our previous publications[9-11]. The FCC-X 
originated from 19 cancer families clinically indistinguish-
able from Lynch syndrome (hereditary non-polyposis 
colon cancer), but screening negative for the known pre-
disposing genes by multiple techniques[12]. We identified 
distinct molecular features in these tumors including high 
frequency of  genomically stable carcinomas with mem-
branous β-catenin, however, the predisposing defects in 
these families remain elusive[9]. The sporadic colorectal 
tumors were selected from a larger cohort with the aim 
to include equal numbers of  tumors with membranous vs 
nuclear β-catenin.
Fresh frozen and/or paraffin derived specimens of  
tumor and matching normal tissues were collected from 
pathology departments of  different hospitals and used 
for immunohistochemical analysis and DNA extraction 
according to standard protocols. All human specimens 
were obtained after informed consent and approvals 
from the appropriate institutional review boards of  the 
Helsinki University Central Hospital.
mRNA expression analysis by microarrays
Analyses were performed using HG-U133 Plus 2.0 array 
(Affymetrix, Santa Clara, CA, United States). The proto-
cols for HG-U133 Plus 2.0 arrays were as described by 
the manufacturer (Affymetrix, Santa Clara, CA, United 
States). Briefly, total RNA was extracted from cell lines 
by RNeasy (Qiagen, Valencia, CA, United States). An 
aliquot of  each RNA sample was run on a 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, CA, United States) 
to visualize and quantify the degree of  RNA integrity. 
Double-stranded cDNA was synthesized from 5 μg of  
total RNA using the GeneChip One-Cycle cDNA syn-
thesis kit, followed by cleanup with the GeneChip Sample 
Cleanup Module, in vitro transcription (IVT) and Biotin 
labeling reaction using the GeneChip IVT Labeling kit, 
and clean-up and quantification of  the biotin-labeled 
cRNA yield by spectrophotometric analysis. All kits were 
from Affymetrix. Fragmentation of  the 8 μg cRNA and 
hybridizations to test chips and the HG-U133 Plus 2.0 
array were carried out according to Affymetrix proto-
cols, and microarrays were processed by the Affymetrix 
Fluidics Station 450 and scanned with an Affymetrix 
GeneChip Scanner 7G. Captured images were analyzed 
using Microarray Suite version 5.0 algorithm (Affymetrix). 
All quality control criteria recommended by Affymetrix 
were observed in the “Test” chips and sample chips.
The hybridization data were pre-processed using 
Robust Multi-array Average (RMA[13]), designed to en-
hance the comparability of  expression measures between 
separate arrays. RMA pre-processing produces a single 
expression measure for each probe set in the Affymetrix 
array which can be readily used in subsequent analyses. 
As duplicate arrays were available for each cell line, the 
median of  the two RMA values was used as the expres-
sion value. Gene assignments of  the probes were extract-
ed from the Affymetrix annotation files and genes with 
ambiguous information about the physical location were 
excluded from the analysis.
EPS8 loss of heterozygosity analysis
For the EPS8 loss of  heterozygosity (LOH) analysis we 
chose two microsatellite markers spanning the EPS8 gene 
locus at Ensembl cytogenetic band 12p12.3 and surround-
ing the gene from both directions (http://www.ensembl.
org). The physical distances between loci in mega-bases 
according to Ensembl are given in parentheses: pter 
D12S1580 - (2.4 Mb) - EPS8 - (0.4 Mb) - D12S1728 qter. 
The polymerase chain reaction (PCR) amplification prim-
ers were from Généthon Microsatellite Maps at http://
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www.genlink.wustl.edu/genethon_frame. The forward 
primers were fluorescently labeled with carboxyfluorescein 
and PCR fragments were run on the ABI3730 sequencer/
genotyper and results analyzed using GeneMapper v3 
software (Applied Biosystems, Forster City, CA, United 
States) as described previously[9]. A sample was scored as 
showing LOH, if  one of  the alleles had decreased 40% 
or more, and borderline LOH or allelic imbalance, if  the 
decrease was 25%-39% for one allele.
Microsatellite instability analysis
Microsatellite instability status was determined using the 
Bethesda panel of  5 microsatellite markers and additional 
markers as described[9,14,15]. Tumors with two or more 
unstable markers were considered to have high-degree 
microsatellite instability (MSI-H), while those with one 
unstable marker had low-degree microsatellite instability 
(MSI-L) and those with no unstable markers were mic-
rosatellite stable (MSS). MSI-H cancers were mostly ex-
cluded from this study cohort to enable the LOH study.
Immunohistochemical analysis
Four-micrometer sections from formalin-fixed paraffin-
embedded tissues were mounted on silanized slides (Dako, 
Glostrup, Denmark) and air-dried overnight at 37 ℃. After 
de-waxing and re-hydration in distilled water, sections were 
subject to heat-induced target retrieval in 1 mmol/L ethyl-
enediaminetetraacetic acid buffer pH 8.0 for 5 min at 750 
W followed by 5 min at 450 W in a microwave oven. Af-
ter cooling, the slides were washed in Tris-buffered saline 
pH 7.2 and subsequent staining steps were performed 
manually with the Dako EnVision+ System, Peroxidase 
(DAB), according to the manufacturer’s instructions 
(Dako, Glostrup, Denmark). In addition, after blocking 
endogenous peroxidase activity, and prior to incubation 
with the primary antibody, the sections were incubated 
with 10% normal (non-immune) goat serum (Dako, 
Glostrup, Denmark) for 30 min. The primary antibodies 
were purified rabbit polyclonal anti EPS8 Antibody (C-
terminal, clone RB4006, Abgent, San Diego, CA, United 
States) and purified mouse monoclonal anti-β-catenin 
antibody (clone 14, BD Transduction Laboratories, Er-
embodegem, Belgium). Paired tumor and normal mucosa 
were in the same section and the normal tissues were 
used as an internal reference for evaluation of  staining 
results. β-catenin immunohistochemical staining for iden-
tification of  its sub-cellular localization and the interpre-
tation of  results were performed as described[9]. β-catenin 
expression was considered aberrant if  there was nuclear 
staining of  more than 10% or cytoplasmic staining of  
more than 50% of  tumor cells (not observed in the 
matching normal tissue). For approximately half  of  the 
tumors, β-catenin data were available from our earlier 
studies[9], while for the rest, these results were generated 
in the present investigation.
EPS8 mutation analysis
All coding exons of  the EPS8 gene were examined 
by direct sequencing. The primer sequences and PCR 
conditions are given in Table 1. EPS8 sequences were 
compared to that of  GenBank accession number RefSeq 
NC_000012.10, and exon information was from En-
sembl ENST00000389337. DNA mutation numbering is 
based on cDNA sequence where +1 corresponds to the 
A of  the ATG translation initiation codon and the initia-
tion codon is codon 1. Sequence changes reported here 
were present in sequence tracing from both the forward 
and reverse direction and were reproducibly found in 2 
independent PCR products from cases of  interest. 
EPS8 methylation analysis
To search for CpG islands in the EPS8 promoter, the 
EMBOSS CpG Plot program was used with default defi-
nitions (http://www.ebi.ac.uk/emboss). Two adjacent 
CpG islands were identified, together spanning 750 bp 
within and upstream of  the untranslated exon number 1. 
This area was divided into two overlapping segments to 
screen cell lines and normal lymphocytes for methylation 
by bisulfite sequencing. The primers for the distal region 
were, forward, 5’-gggagatttttagggatttgatgg-3’ and reverse, 
5’-ccaaattatcaaaaccacaatcaaaatc-3’, and for the proximal re-
gion (closest to and in part including the untranslated exon 
1), forward, 5’-ttagttagttttgttagggtatttttgg-3’ and reverse, 
5’-ctaactactacctataaaatctaaaacc-3’. Only the distal region 
showed any evidence of  methylation, which is why we fo-
cused on this region when designing methylation-specific 
PCR (MSP) assays for the studies of  patient specimens. 
MSP[11] was performed to separately amplify either 
methylated or unmethylated alleles from the distal region 
of  the EPS8 promoter (see above). Two alternative pairs 
of  primers (MF1 + MR1, or MF3 + MR3) were used for 
the methylated reaction, and primers UF1 + UR1 for the 
unmethylated reaction. The primer sequences were: MF1, 
5’-tggttattagatgcgttttgtttgtc-3’, MR1, 5’-gtataaaaaacttc-
gcccccgacg-3’; MF3, 5’-ggtgttgtaatttgagcgtttttttc-3’, MR3, 
5’-aacgtataaaaaacttcgcccccg-3’; and UF1, 5’-ttggttattag-
atgtgttttgtttgtt-3’, UR1 5’-ccaacaaaaataaacaccccaaaca-3’. 
DNA (1 μg) was modified with sodium bisulfite treatment 
(CpGenome DNA Modification kit, Chemicon) and sub-
jected to MSP. MSP was performed in a volume of  25 μL 
containing 24 ng of  bisulfite-modified template per reac-
tion with HotStarTaq DNA polymerase (Qiagen). Cycling 
conditions were according to the manufacturers’ standard 
cycling protocol for HotStarTaq DNA polymerase, with 
35 cycles. Annealing temperatures were 58 ℃ for the 
methylated reaction MF1 + MR1, 64 ℃ for the methyl-
ated reaction MF3 + MR3, and 58 ℃ for the unmethylated 
reaction. MSP products were run through 2%-3% agarose 
gel, stained with ethidium bromide, and visualized with 
ultraviolet transillumination. All sodium bisulfite modifica-
tions and MSP runs were repeated at least twice. A negative 
control without template was included in each MSP run.
RESULTS
RKO is a special colon cancer cell line as it lacks constitu-
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tive β-catenin regulated transcription compared to other 
colon cancer cell lines[8]. To detect genes that show the 
most remarkable differential expression in the RKO cell 
line compared to all the other cell lines (HCA7, KM12, 
LoVo, DLD1, HCT116, SW48, and LIM1215, each being 
mismatch repair-deficient like RKO), maximum deviance 
in signal between RKO and the remaining lines was cal-
culated for each Affymetrix probe. When identifying pu-
tative over-expressed genes, the deviance was defined as 
the difference between the signal in RKO and the maxi-
mum signal in the other cell lines. In the case of  under-
expressed genes, the deviance was defined as the differ-
ence between the signal in RKO and the minimum signal 
in the other cell lines. The Affymetrix probe “202609_at” 
corresponding to the EPS8 gene showed remarkable re-
duction in the RKO cell line when compared to the other 
cell lines. The signal detected in RKO was 118, whereas 
the other cell lines showed signals of  1454, 1361, 3792, 
429, 683, 758 and 1804 (Log2 ratio-3.53).
Most patient samples were MSS apart from 5/43 (12%) 
which showed the MSI phenotype. By immunohistochemi-
cal analysis of  clinical specimens, normal colonic mucosa 
showed dot-like supranuclear cytoplasmic expression pat-
tern of  EPS8 protein (Figure 1A). In some cases we no-
ticed a gradient of  expression with more intense staining at 
the luminal surface that faded away towards the intestinal 
crypts (Figure 1B). Colorectal adenomas and carcinomas 
showed three patterns of  expression compared to their 
matching normal mucosae. 19 (4 adenoma, 15 carcinoma) 
out of  51 tumors (37%) showed tumor specific EPS8 pro-
tein loss, 5 (2 adenoma, and 3 carcinoma) out of  51 (10%) 
showed marked overexpression, while 27/51 tumors 
(53%) showed retained expression comparable to what 
was observed in the matching normal mucosae (Table 2, 
Figure 1C-F). However, there was no significant correla-
tion between EPS8 expression pattern and β-catenin sub-
cellular localization (in contrast to the finding in the RKO 
cell line), or tumor stage and location within the colon.
3899 August 7, 2012|Volume 18|Issue 29|WJG|www.wjgnet.com
Table 1  Epidermal growth factor receptor pathway substrate 8 genomic primers (ENST00000389337)
Primer Sequence Primer for sequence Tm PCR fragment (bp)
EPS8ex1F tcctggcagcaacacatatt F 59 227
EPS8ex1R ccaaatcaaattcccccaaa 62
EPS8ex2F aacccaacacaatgaccttttt 60 251
EPS8ex2R tcactgcctcattccaaaca R 60
EPS8ex3F gagatagccacatgataccaaca 59 195
EPS8ex3R tgttcctcaagggtcactctaaa F 60
EPS8ex4F tctttttcctttttgccaat 56 280
EPS8ex4R ttccatccattttcaaacaatc R 58
EPS8ex5F gattgtttgaaaatggatggaa F 59 261
EPS8ex5R aaagctcccagacaatctgc 59
EPS8ex6F tcagacaaggaacaatcccttt F 60 251
EPS8ex6R tttttctaactctttggggaaaaa 60
EPS8ex7F agtaccacaagttgagttaattgat F 55 264
EPS8ex7R tcccaacccaaagtaagtgttc 60
EPS8ex8F ggcaaatggtcctccttttt F 60 206
EPS8ex8R ccagtgatctaaaggcgactc 59
EPS8ex9F tgggctgcttccttttctaa F 60 280
EPS8ex9R ctggagatctaaccaggcatt 58
EPS8ex10F cctctcctctcgcttatttca F 58 234
EPS8ex10R cacacccccacaaaatctat 57
EPS8ex11F gaccgtcccctctgtgtcta F 60 229
EPS8ex11R ccagacagacacttggggtta 60
EPS8ex12F cttgtttttgccatgggttt F 60 265
EPS8ex12R aaggcattataggtggtaaatgct 59
EPS8ex13F tatgccttcattccctcctg F 60 297
EPS8ex13R tgaataaaatgagaacttgcaatca 60
EPS8ex14F tgacctgagtgctgattcaaa F 59 274
EPS8ex14R gacactgtcacctctgttagcac 59
EPS8ex15F ctttaggaagagctagcagaat 54 250
EPS8ex15R aatacttttgaaggaaagtttagttat R 54
EPS8ex16F gggaacttctttcgtagaatgg F 59 267
EPS8ex16R aagagtgataacttcgtaaatgtgt 56
EPS8ex17F aaagtataatttgttttcctagcc F 55 315
EPS8ex17R tgcctccctgggaaacttac 61
EPS8ex18F ggggttctagagagggtgatgt F 61 292
EPS8ex18R tgttgtacacacagaattgcaaag 60
EPS8ex19F tttctcctttgtttgtaggcaat 59 256
EPS8ex19R aatagttgtttccagagctttcaa R 59
EPS8ex20F gcagcctgcacaagtcagta F 60 203
EPS8ex20R aatgccaaaaacaatggagtt 59
EPS8: Epidermal growth factor receptor pathway substrate 8; PCR: Polymerase chain reaction; F: Forward; R: Reverse.
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As possible mechanisms underlying expression chang-
es, LOH, mutation, and promoter methylation were evalu-
ated. We report LOH at EPS8 locus if, at least, one of  the 
two markers D12S1580 and D12S1728 showed a clear cut 
LOH (40% or more reduction) while borderline-LOH (ra-
tio reduction ranging from (25%-39%) at one marker only 
was ignored. Overall, 20/51 (39%) tumors showed EPS8 
locus LOH with similar frequencies in adenomas (40%) 
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Table 2  Analysis of epidermal growth factor receptor pathway substrate 8 gene status and protein expression in uncultured tumor 
specimens  n  (%)
Total number Membranous β-catenin LOH1 EPS8 protein loss EPS8 mutation2 Methylation3
Sporadic carcinomas 22 10/22 (45)   7/19 (37) 11/22 (50)   0/11 0/7
Sporadic adenomas 15   4/10 (40)   6/15 (40)   4/14 (29) 0/4 ND
FCC-X 21 11/18 (61)   7/17 (41)   4/15 (27) ND ND
Total 58 20/51 (39) 19/51 (37)   0/15 0/7
1Based on informative (i.e., constitutionally heterozygous) cases; 2Cases with protein loss by immunohistochemistry and/or presence of loss of 
heterozygosity (LOH) were selected for this analysis; 3Cases were selected on the basis of immunohistochemical protein loss without LOH. ND: Not done; 
FCC-X: Familial colon cancer type X; EPS8: Epidermal growth factor receptor pathway substrate 8.
DC
BA
FE
Figure 1  Epidermal growth factor receptor pathway substrate 8 immunohistochemistry. A: Normal colon mucosa with dot-like, supranuclear expression; B: 
Normal colon mucosa with clear gradient of expression stronger at the luminal aspect compared to the crypt bases; C: Marked reduction to complete loss of epider-
mal growth factor receptor pathway substrate 8 (EPS8) expression in adenoma (lower left) compared to normal mucosa (upper right); D: EPS8 positive adenoma; E: 
Marked reduction to complete loss of EPS8 expression in carcinoma (lower left) compared to normal mucosa (upper right); F: EPS8 positive carcinoma. 
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and carcinomas (37%-41%) (Table 2). LOH was observed 
in 6/16 (38%) of  informative tumors with absent EPS8 
protein vs 9/39 (23%) of  cases with retained or elevated 
protein expression (P = 0.53).
All coding exons and flanking intronic regions of  
the EPS8 gene were examined by direct sequencing. The 
focus of  this analysis was the cell line RKO and tumors 
with loss of  EPS8 expression and/or LOH. We also in-
cluded one of  the control cell lines (HCA7 because of  
other special features[16]) We identified only one tumor 
specific missense mutation c.794C>T (p.R265C) in exon 
8 in the RKO cell line. Since the matching normal tissue 
for the RKO cell line was not available, we further ana-
lyzed more than 100 normal DNA samples and none of  
them showed this change. To our knowledge, this nucleo-
tide change is also not reported in any sequence or single 
nucleotide polymorphism (SNP) database. The nature of  
the amino acid change suggests that this is not likely to 
be a SNP since Arginine (R) is a positively charged, large 
polar amino acid that mostly prefers to substitute for the 
other positively charged amino acid Lysine, although in 
some circumstances it will also tolerate a change to other 
polar amino acids, but substitution with the small amino 
acid cysteine (C) is not tolerated in any cellular location[17]. 
We tested this particular substitution using the SIFT pro-
gram (http://blocks.fhcrc.org/sift/SIFT.html) that sorts 
intolerant from tolerant amino acid substitutions based 
on evolutionary conservation, and cysteine substitution 
was regarded as intolerant.
Regarding EPS8 methylation analysis, our very first 
observation was that the well-established human lym-
phoblastoid cell line TK6 was methylated in the distal 
region of  the EPS8 promoter, which indicated that the 
promoter was sensitive to methylation in general (Figure 
2A). EPS8 promoter methylation was examined by bi-
sulfite sequencing in all cancer cell lines. These included 
cell lines in which the MLH1 promoter was known to 
be methylated (RKO, KM12, HCA7) as well as cell lines 
with unmethylated MLH1 promoter (HCT15, HCT116, 
LoVo, LIM1215)[11]. Only RKO was methylated (Figure 
2A). Encouraged by EPS8 methylation in RKO, we de-
signed MSP reactions to investigate EPS8 methylation 
status in patient specimens of  colorectal cancer. We 
focused on those cases that had no LOH at chromo-
some 12 markers (including cases that were uninforma-
tive for LOH), yet EPS8 protein was reduced or lost by 
immunohistochemistry, suggesting that there had to be 
alternative mechanisms for inactivation. There was no 
methylation in any of  the seven tumor specimens ana-
lyzed, including five MSS tumors and two with MSI (Fig-
ure 2B). Given the lack of  methylation in these samples 
of  perhaps the highest interest, we did not extend these 
analyses to additional specimens.
DISCUSSION
Our data shed light on the role of  EPS8 in tumorigenesis 
in several important respects. EPS8 is involved in actin 
dynamics through its actin barbed-end capping activ-
ity and its ability to modulate Rac activity. Accordingly, 
EPS8 is crucial for the formation of  actin networks that 
support cellular structures such as lamellipodia, filopodia, 
stress fibers and focal adhesions[18]. It appears that this is 
the most significant function of  EPS8 in carcinogenesis 
also, since it did not colocalize with epidermal growth 
factor receptors but colocalized with F-actin in circu-
lar ruffles and at the leading edge of  pancreatic cancer 
cells[19]. The data presented here support an important 
role of  EPS8 in maturation and differentiation of  the 
normal human colonic mucosa since normal colonic mu-
cosa showed strong constitutive supranuclear cytoplasmic 
expression of  EPS8 with increasing intensity towards 
the luminal surface away from the crypt base. These data 
are consistent with the well established role of  EPS8 in 
the maturation of  intestinal epithelium in C. elegans[5] and 
the previously described expression pattern in pancreatic 
ductal cells[19]. Potential roles of  EPS8 in normal colonic 
epithelium might include the migration of  proliferating 
cells from the bases of  the crypt to the colonic luminal 
surface and/or stabilization of  cell-cell junctions, as EPS8 
was shown to be involved in cell-cell junction stability in 
fibroblasts[20], and EPS8 knockdown impaired actin cell-
cell junction in confluent pancreatic cancer cells[19].
Regarding colon carcinoma, we noticed high levels 
of  EPS8 mRNA in all cell lines except RKO. However, 
immunohistochemical analysis of  EPS8 protein in un-
cultured tumor biopsies showed that only around 10% 
of  uncultured patient biopsies showed protein overex-
pression. This discrepancy between the cell line mRNA 
approach and patient biopsies’ protein expression was 
consistent with the observation in pancreatic ductal ad-
enocarcinomas[19] and may be explained by the apparent 
need of  the cell lines to over-express motility and inva-
sion markers. We are currently undertaking studies to ex-
1        2       3       4       5        6       7       8       9       10A
B 1        2       3       4       5        6       7       8       9       10
Figure 2  Methylation-specific polymerase chain reaction assays for 
epidermal growth factor receptor pathway substrate 8 gene. A: Cell lines 
analysis; upper panel is the unmethylated (UF1 + UR1) reaction and lower panel 
is the methylated (MF1 + MR1) reaction. Sample order in both panels from left to 
right is 1, RKO; 2, LoVo; 3, LIM1215; 4, HCA7; 5, HCT116; 6, KM12; 7, HCT15; 8, 
TK6 (a lymphoblastoid cell line); 9, unmethylated (negative) control; 10, water; B: 
Primary uncultured colon cancer analysis; upper panel is the unmethylated reac-
tion and lower panel is the methylated reaction (MF3 + MR3). Sample order in 
both panels from left to right is 1-7, uncultured colon cancer specimens; 8, RKO 
(used as methylated control); 9, unmethylated (negative) control; 10, water.
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plore the role of  miRNA in posttranscriptional regulation 
of  EPS8 protein expression. However, studies showed 
good correlation between mRNA and protein levels 
within the same tumor model[21].
The remarkable finding in this work was loss of  EPS8 
protein expression in subsets of  colon adenoma and car-
cinoma. This finding is intriguing given the large number 
of  published reports on EPS8 upregulation in different 
types of  cancers, including those of  the colon[7,19,22-24]. We 
also noted this upregulation at the levels of  mRNA and 
protein expression in some tumors as discussed above. A 
careful analysis of  the published reports shows, however, 
that most cases of  EPS8 upregulation were characteristic 
of  advanced stage and metastatic cancers[7,19,23,24]. The pub-
lished literature suggests that EPS8 is most likely to be up-
regulated at the stage of  metastasis. This hypothesis is best 
highlighted by the finding of  EPS8 upregulation in the 
metastatic cell line SW620 as compared to its primary co-
lon cancer cell line SW480[7]. These two cell lines are a well 
established model that have been used to study the mark-
ers associated with metastasis in colon carcinomas[25,26]. 
Similarly, the metastatic HN12 cells expressed high levels 
of  EPS8 compared to its primary squamous cell carcino-
ma-derived cell line HN4[22]. In pancreatic cancer, cell lines 
from primary tumors had low levels of  EPS8 mRNA ex-
pression; cell lines from pancreatic cancer metastases had 
medium levels of  EPS8 mRNA expression; and a cell line 
derived from malignant ascites (AsPC-1) had high levels of  
EPS8 mRNA expression[19]. These data could explain the 
apparent lack of  mutation in our study, particularly in those 
tumors with loss of  EPS8 protein which should leave a 
space for upregulation and overexpression at later stages; 
since reversion mutations are known to be extremely rare. 
In this regard, epigenetic and other regulatory mechanisms 
that could be easily reversed would be a preferable mode 
for controlling this gene expression status. Consistent with 
this, we noted the susceptibility of  the EPS8 promoter 
to methylation in the lymphoblastoid TK6 cells (Figure 
2A) and its methylation in the RKO cell line associated 
with EPS8 mRNA underexpression. This is in agreement 
with RKO being a prototype of  CpG island methylator 
phenotype that is usually observed in combination with 
MSI tumors[27]. We, however, did not observe promoter 
methylation in the primary tumors considered to have the 
highest a priori likelihood for methylation, suggesting that 
EPS8 inactivation in these tumors occurred by other, as yet 
unknown mechanisms. 
In conclusion, we report EPS8 loss of  expression in 
colorectal adenomas and carcinomas and propose that 
EPS8 downregulation plays a role in the development of  
these tumors. 
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